AstraZeneca PLC (AZNCF)

OTCMKTS · Delayed Price · Currency is USD
145.63
+3.15 (2.21%)
Jun 4, 2025, 12:09 PM EDT
-5.30%
Market Cap 223.00B
Revenue (ttm) 54.98B
Net Income (ttm) 7.77B
Shares Out n/a
EPS (ttm) 4.97
PE Ratio 28.69
Forward PE 15.46
Dividend 3.10 (2.18%)
Ex-Dividend Date Feb 20, 2025
Volume 1,200
Average Volume 1,752
Open 145.02
Previous Close 142.48
Day's Range 145.02 - 147.08
52-Week Range 120.64 - 175.00
Beta 0.17
RSI 54.29
Earnings Date Jul 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Sector Healthcare
Founded 1992
Employees 94,300
Stock Exchange OTCMKTS
Ticker Symbol AZNCF
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial Statements

News

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

22 hours ago - CNBC

AstraZeneca CEO Pascal Soriot on breast cancer drug trial

Pascal Soriot, CEO of AstraZeneca, said on Monday that he sees the pharma company's breast cancer blood test, which tracks signs of returning cancer, as "the future of cancer treatment."

2 days ago - CNBC Television

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...

2 days ago - CNBC Television

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial, the Trump administration's 'most favored nation' policy, R&D innovation, ...

2 days ago - CNBC

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

2 days ago - Investor's Business Daily

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...

2 days ago - Benzinga

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

Daiichi Sankyo and AstraZeneca's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes ...

2 days ago - Benzinga

Experimental AstraZeneca pill helps cut risk of breast cancer progression

CNBC's Joe Kernen reports on the latest news.

2 days ago - CNBC Television

Experimental AstraZeneca pill helps cut risk of breast cancer progression

CNBC's Joe Kernen reports on the latest news.

2 days ago - CNBC

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca's DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC TROPION-...

3 days ago - Benzinga

'Transformational' new drug could stop breast cancer tumours before they grow, trial finds

A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found.

3 days ago - Skynews

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding...

3 days ago - Reuters

AstraZeneca unveils drug to treat mutating breast cancer before it starts to grow

Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year

3 days ago - Financial Times

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbocic...

3 days ago - Business Wire

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting Positive results from the DESTINY-G...

4 days ago - Benzinga

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid...

5 days ago - PRNewsWire

Looking Into AstraZeneca's Recent Short Interest

AstraZeneca's (NYSE: AZN) short percent of float has risen 50.0% since its last report. The company recently reported that it has 7.34 million shares sold short , which is 0.24% of all regular shares...

5 days ago - Benzinga

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.

13 days ago - Business Wire

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

SERENA-6 plenary presentation will feature next-generation oral SERD camizestrant in 1st-line advanced HR-positive breast cancer MATTERHORN plenary presentation will showcase perioperative treatment w...

14 days ago - Benzinga

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S...

14 days ago - Business Wire